phrykt

OS Therapies Inc (OSTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of OSTX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No OSTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OSTX short interest

Moderate short interest. 6.0% of OSTX shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 110%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.76M OSTX shares were sold short, 6.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 357,247 shares, buying them all back would take about 7.7 trading days (days to cover).

Shares short, % of all shares

5.98%May 15Oct 307.57%

Days to cover

7.7May 15Oct 3010.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.76M5.98%-2%357,2477.7
Oct 15, 20262.82M6.12%+9%963,5262.9
Sep 30, 20262.60M5.63%+23%668,1823.9
Sep 15, 20262.11M4.58%-23%839,0522.5
Aug 31, 20262.76M5.99%+7%419,3986.6
Aug 14, 20262.58M5.60%-7%282,8819.1
Jul 31, 20262.77M7.01%+5%324,7128.5
Jul 15, 20262.63M6.66%+17%1.02M2.6
Jun 30, 20262.25M5.70%+11%894,5252.5
Jun 15, 20262.03M5.14%+23%642,0863.2
May 29, 20261.66M4.19%+26%819,2732.0
May 15, 20261.32M3.33%-5%595,4542.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

OS Therapies company events

OS Therapies filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 19, 2026.

  1. Oct 19, 2026AgreementOS Therapies Incorporated commenced an offer to less than 10 accredited investors that beneficially own certain of the Company’s outstanding warrants to exercise, or pre-fund the exercise of, their Existing Warrants for cash at a reduced exercise price of $1.30 per share pursuant to inducement… Filing
  2. Oct 5, 2026LeadershipOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  3. Sep 10, 2026AnnouncementOS Therapies Incorporated filed with the U.S. Securities and Exchange Commission a prospectus supplement, which forms a part of the Company’s registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 25, 2025. Filing
  4. Sep 9, 2026LeadershipThe stockholders of OS Therapies Incorporated approved and adopted the amendment and restatement of the Company’s 2023 Incentive Compensation Plan, as amended, at its 2026 annual meeting of stockholders. Filing
  5. Aug 21, 2026AgreementOS Therapies Incorporated entered into an Open Market Sale Agreement℠ with Jefferies LLC, pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program. Filing
  6. Aug 12, 2026AgreementOS Therapies Incorporated, together with its wholly owned subsidiaries, entered into a securities purchase agreement with the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a… Filing
  7. Aug 6, 2026AgreementLeonite 2026 Secured Financing As previously disclosed, on June 30, 2026, OS Therapies Incorporated, together with its wholly owned subsidiaries, entered into a securities purchase agreement with Leonite Fund I, LP and related transaction documents, pursuant to which the Company issued and sold to… Filing
  8. Jul 29, 2026AgreementEnded an important agreement. Filing
  9. Jul 2, 2026LeadershipKarim Galzahr notified the Company of his resignation from the Company’s board of directors, effective immediately. Filing
  10. Apr 30, 2026AnnouncementShared information with investors. Filing
  11. Apr 2, 2026AgreementOS Therapies Incorporated entered into a securities purchase agreement with the purchasers identified on the signature pages thereto, pursuant to which the Company offered for sale to the Purchasers in a registered direct offering an aggregate of 2,505,073 shares of its common stock and, in lieu… Filing
  12. Mar 31, 2026AnnouncementOS Therapies Incorporated filed with the U.S. Securities and Exchange Commission a prospectus supplement, which forms a part of the Company’s registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. Filing
  13. Mar 6, 2026AgreementOS Therapies Incorporated entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement, (i) 10.0% original issue discount unsecured convertible promissory notes and (ii) warrants to… Filing
  14. Feb 13, 2026AnnouncementAs previously announced, on January 10, 2026, OS Therapies Incorporated entered into inducement offer letter agreements with less than 10 accredited investors that hold certain existing warrants of the Company to purchase up to an aggregate of 5,382,148 shares of the Company’s common stock… Filing
  15. Jan 12, 2026AgreementOS Therapies Incorporated entered into inducement offer letter agreements with less than 10 accredited investors that hold certain existing warrants of the Company to purchase up to an aggregate of 5,382,148 shares of the Company’s common stock, originally issued to the Holders in connection with… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

OS Therapies financials

Famous investors that hold OSTX

1 of the 50 well-known investors we track reported holding OSTX in their latest 13F filing. The largest position is Ken Griffin's, worth $393K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026245,856$393K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named OSTX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026Thomas A. Satterfield, Jr.13G/A9.9%
Nov 10, 2026Thomas A. Satterfield, Jr.13G/A9.9%

Questions about OS Therapies Inc (OSTX) stock

Are OSTX insiders buying or selling?

No OSTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in OSTX?

As of Oct 30, 2026, 2.76M OSTX shares were sold short, 6.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 357,247 shares, buying them all back would take about 7.7 trading days (days to cover). See the history.

Which famous investors hold OSTX?

1 of the 50 well-known investors we track reported OSTX in their latest 13F filing, including Ken Griffin. The largest position is worth $393K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.